Iliopsoas hematoma in patients with COVID-19 on low-molecular-weight heparin treatment | Zendy

Gianluca Sottilotta | Zendy; Carmelo Mangano | Zendy; Rosa Basile | Zendy; Carmela Falcone | Zendy; Francesca Luise | Zendy; Demetrio Megalizzi | Zendy; G. Nicolò | Zendy; Vincenzo Oriana | Zendy; Angela Piromalli | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Iliopsoas hematoma in patients with COVID-19 on low-molecular-weight heparin treatment

Author(s) -

Gianluca Sottilotta,

Carmelo Mangano,

Rosa Basile,

Carmela Falcone,

Francesca Luise,

Demetrio Megalizzi,

G. Nicolò,

Vincenzo Oriana,

Angela Piromalli

Publication year - 2021

Publication title -

sage open medical case reports

Language(s) - English

Resource type - Journals

ISSN - 2050-313X

DOI - 10.1177/2050313x211016991

Subject(s) - medicine , iliopsoas , heparin , hematoma , covid-19 , complication , surgery , low molecular weight heparin , virology , disease , outbreak , infectious disease (medical specialty)

Patients with COVID-19 are at high risk of thromboembolic events; for this reason, the use of heparin is largely recommended but, in addition to thrombotic complications, bleeding is a significant cause of morbidity in patients with COVID-19. Idiopathic iliopsoas hematoma is a very rarely described hemorrhagic complication in patients with COVID-19. We report here two cases of iliopsoas hematoma in male patients with COVID-19 and being treated with heparin.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research